-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $615

Benzinga·05/06/2026 15:43:19
Listen to the news
Barclays analyst Eliana Merle maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and raises the price target from $607 to $615.